异基因造血细胞移植后青少年和青年存活者随访终止概率高
该研究基于日本移植登记数据库,纳入1974至2013年间首次接受异基因造血细胞移植后存活超过2年的17980例患者,分析随访终止情况。中位移植年龄34岁,4987例患者终止了移植中心随访。随访终止的累积发生率在移植后10年为28%(95%CI 27%-29%),25年增至67%(95%CI 65%-69%)。青少年和青年(AYA)患者在整个期间随访终止概率最高,儿科患者移植后16年内最低。
要点
- AYA患者在异基因HCT后随访终止概率最高,儿科患者最低。
- 随访终止累积发生率10年为28%,25年增至67%。
- 随访终止多由医生基于患者身体状况良好而决定。
核心结论
- 异基因造血细胞移植后AYA存活者随访终止概率高,提示需要对医生和患者进行关于长期随访重要性的教育,即使存活者身体状况良好。
研究设计与样本
- 基于日本移植登记数据库的分析,纳入1974至2013年间首次接受异基因造血细胞移植后存活超过2年的17980例患者。
- 中位移植年龄34岁(范围0-76岁)。
主要发现
- 4987例患者终止了移植中心随访。
- 随访终止的累积发生率在移植后10年为28%(95%CI 27%-29%),25年为67%(95%CI 65%-69%)。
- 儿科患者移植后16年内随访终止概率最低,AYA患者在整个期间随访终止概率最高。
- 随访终止最常由医生基于患者身体状况良好而决定。
- 多因素分析确定6个与随访终止相关的因素:AYA患者、女性患者、标危恶性肿瘤或非恶性疾病、无关骨髓移植、2000至2005年间移植、无慢性移植物抗宿主病。
关键数值与推荐
- 随访终止累积发生率:10年28%(95%CI 27%-29%),25年67%(95%CI 65%-69%)。
- 多因素分析确定的6个随访终止相关因素:AYA患者、女性患者、标危恶性肿瘤或非恶性疾病、无关骨髓移植、2000至2005年间移植、无慢性移植物抗宿主病。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The need for long-term follow-up (LTFU) after allogeneic hematopoietic cell transplantation (HCT) has been increasingly recognized for managing late effects such as subsequent cancers and cardiovascular events. A substantial population, however, has already terminated LTFU at HCT centers. To better characterize follow-up termination, we analyzed the Japanese transplant registry database. The study cohort included 17 980 survivors beyond 2 years who underwent their first allogeneic HCT between 1974 and 2013. The median patient age at HCT was 34 years (range, 0-76 years). Follow-up at their HCT center was terminated in 4987 patients. The cumulative incidence of follow-up termination was 28% (95% confidence interval [CI], 27%-29%) at 10 years, increasing to 67% (95% CI, 65%-69%) at 25 years after HCT. Pediatric patients showed the lowest probability of follow-up termination for up to 16 years after HCT, whereas adolescent and young adult (AYA) patients showed the highest probability of follow-up termination throughout the period. Follow-up termination was most often made by physicians based on the patient's good physical condition. Multivariate analysis identified 6 factors associated with follow-up termination: AYA patients, female patients, standard-risk malignancy or nonmalignant disease, unrelated bone marrow transplantation, HCT between 2000 and 2005, and absence of chronic graft-versus-host disease. These results suggest the need for education of both physicians and patients about the importance of LTFU, even in survivors with good physical condition. The decreased risk for follow-up termination after 2005 may suggest the increasing focus on LTFU in recent years.
引用
- Miyamura K, Yamashita T, Atsuta Y, et al. High probability of follow-up termination among AYA survivors after allogeneic hematopoietic cell transplantation. Blood Adv. 2019. PMID: 30728138. doi:10.1182/bloodadvances.2018026039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。